Combined laser and crosslinking for keratoconus
Part of Eyes & vision clinical trials.
This trial tests a new combined treatment for keratoconus that includes both a surface laser (phototherapeutic keratectomy) and corneal collagen crosslinking (CXL). It may help strengthen your cornea and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your keratoconus must be getting worse (progressive) and your doctor has said you need a treatment called corneal collagen crosslinking (CXL).
- The thinnest part of your cornea must be at least 420 micrometers thick.
- You cannot have any other eye disease that is causing vision loss (besides keratoconus).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies collagen cross-linking, a procedure meant to strengthen a weakened cornea in people with keratoconus. It may help slow the bulging/weakening of the cornea and improve vision, and the study also uses special imaging to check changes over time.
This trial tests two different laser-based procedures to treat keratoconus, a condition that weakens and bulges the cornea. The goal is to see which approach better strengthens the eye and improves vision.
This study tests a same-day procedure that strengthens the cornea (the clear front part of the eye) in both eyes using a special light treatment, called cross-linking. It may help slow or stop the progression of keratoconus, a condition where the cornea becomes cone-shaped and causes blurry vision.
This study looks at how donor corneas (for deep lamellar corneal transplant in keratoconus) are prepared using corneal collagen cross-linking, to see if it improves outcomes for people with keratoconus. You may be eligible if you meet vision and cornea shape/thickness requirements and can return for long follow-up.
This Phase 2 study tests whether a procedure called PXL‑Platinum 330 can safely and effectively strengthen corneas that are thinning (such as keratoconus or related conditions). It aims to see if the treatment can help stabilize or improve the cornea’s shape while keeping side effects low.
This trial tests two different UV light exposure times (18 minutes vs. 24 minutes) during a corneal crosslinking procedure for people with keratoconus or similar corneal thinning conditions. The goal is to see if the shorter time works as well as the longer one.
Hear when a new Keratoconus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.